Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Celecoxib:Nicotinamide Dissociation: Using Excipients to Capture the Cocrystal's Potential

Journal Article · · Molecular Pharmaceutics
DOI:https://doi.org/10.1021/mp0700108· OSTI ID:929800

The cocrystal of celecoxib and nicotinamide (Cel:Nic) was crystallized from chloroform in a 1:1 ratio, and the structure has been solved from powder X-ray diffraction data. The dissolution and solubility of Cel:Nic are medium dependent and can be attributed to differences in conversion of Cel:Nic to celecoxib polymorphs I and III (Cel-I and Cel-III). The presence of low concentrations of surfactants facilitates the rapid conversion of neat Cel:Nic to large aggregates of Cel-III that dissolve more slowly than commercial Cel-III into 1% SDS solution. In contrast, combinations of Cel:Nic with both 1-10% solid SDS and PVP wet rapidly and convert to a mixture of amorphous celecoxib and a micron-sized crystalline celecoxib form IV (Cel-IV), which has recently been shown to be up to 4-fold more bioavailable than marketed Cel-III. More than 90% of the suspended material dissolves within 2 min at 37 C when transferred to 1% SDS solution. This example highlights the importance of exploring the form conversion of cocrystals in aqueous media prior to pharmacokinetic studies, and illustrates the potential of simple formulations to overcome the limitations caused by rapid dissociation of cocrystals and recrystallization of poorly soluble forms in aqueous media.

Research Organization:
Brookhaven National Laboratory (BNL) National Synchrotron Light Source
Sponsoring Organization:
Doe - Office Of Science
DOE Contract Number:
AC02-98CH10886
OSTI ID:
929800
Report Number(s):
BNL--80347-2008-JA
Journal Information:
Molecular Pharmaceutics, Journal Name: Molecular Pharmaceutics Journal Issue: 3 Vol. 4
Country of Publication:
United States
Language:
English

Similar Records

Celecoxib: Nicotinamide Dissociateion: Using Excipients to Capture the Cocrystal's Potential
Journal Article · Sun Dec 31 23:00:00 EST 2006 · Molecular Pharmaceutics · OSTI ID:929916

Heterogeneous Reduction of PuO2 with Fe(II): Importance of the Fe(III) Reaction Product
Journal Article · Sun May 01 00:00:00 EDT 2011 · Environmental Science & Technology, 45(9):3952-3958 · OSTI ID:1015893